Vesugen
also known as KED, Lys-Glu-Asp, Vezugen, T-38
Synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulatory peptide school. Designed for vascular endothelium targeting. Animal models demonstrate normalisation of endothelin-1 expression in atherosclerotic and restenotic vessels, restoration of connexin-mediated cell interactions, and stimulation of Ki-67-associated proliferation in aged endothelial cells. Proposed mechanism: epigenetic modulation via promoter binding to MKI67 and endothelial marker genes. Clinical data limited to Russian-language case series in elderly populations with vascular insufficiency.
At a glance
SQ / IM · Protocol varies
Primary target — Vascular endothelial cell nucleus — MKI67 gene promoter.
Pathway — KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑.
Downstream effect — Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial cultures [kozlov-2016][khavinson-2014].
Origin — Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator.
Feedback intact — Not applicable — does not operate via hormone axis.
| Parameter | Value |
|---|---|
| Standard dose (reported) | Not standardised — Russian clinical case seriesProtocols vary; no FDA-approved regimen. |
| Route | Subcutaneous or intramuscular |
| Frequency | Not specified in available literature |
| Duration | Case series report treatment courses in elderly arterial insufficiency |
| Evidence basis | Animal models (atherosclerosis, restenosis, aging) · Russian case series |
| Half-life | Not reportedTripeptides typically cleared rapidly. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- — Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context
- 01Preparation
Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.
- 02Injection site
Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.
- 03Timing
No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.
- 04Storage
Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).
Sources
of 43 rendered claims carry a resolvable citation.
- [khavinson-2014]Khavinson 2014 — [Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data].
journal, 2014 - [kitachev-2014]Kitachev 2014 — [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].
journal, 2014 - [kozlov-2016]Kozlov 2016 — [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis].
journal, 2016